Skip to main content

Clinical Trials Using Dexamethasone

Review the clinical trials studying dexamethasone on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 101-125 of 140

Belumosudil Mesylate With and Without Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Mezigdomide plus Ixazomib and Dexamethasone for the Treatment of Relapsed and Refractory Multiple Myeloma
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma
Status: Active
Location: 3 locations
Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma
Status: Active
Location: Mayo Clinic in Rochester, Rochester, Minnesota
Genetically Engineered Cells (TGFBR2 KO CAR27/IL-15 NK cells) for the Treatment of Relapsed or Refractory Myeloid Malignancies
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients with Acute Lymphoblastic Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
LP-118 in Combination with Ponatinib, Vincristine and Dexamethasone for the Treatment of Relapsed or Refractory T Acute Lymphoblastic Leukemia and T Lymphoblastic Lymphoma
Status: Active
Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois
Brexucabtagene Autoleucel as Consolidation after Inotuzumab, Blinatumomab and Mini-HCVD or HCVAD for the Treatment of Relapsed/Refractory and Newly Diagnosed B-cell Acute Lymphocytic Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Palbociclib, Bortezomib, Dexamethasone, and Doxorubicin for the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia, RELPALL2 Study
Status: Active
Location: Lucile Packard Children's Hospital Stanford University, Palo Alto, California
Carfilzomib-Based Chemotherapy before Autologous Stem Cell Transplant for the Treatment of Multiple Myeloma
Status: Active
Location: Hackensack University Medical Center, Hackensack, New Jersey
SX-682 in Combination with Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma
Status: Active
Location: Roswell Park Cancer Institute, Buffalo, New York
Talquetamab in Combination with Iberdomide and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Status: Active
Location: University of California San Francisco, San Francisco, California
Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma after CD38- and BCMA-Targeted Therapies
Status: Active
Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Venetoclax in Combination with Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma
Status: Active
Location: Mayo Clinic in Rochester, Rochester, Minnesota
Genetically Engineered Cells (TGFβR-2 KO CD70 CAR NK Cell Therapy) with Lymphodepleting Chemotherapy for the Treatment of Unresectable or Metastatic Refractory Clear Cell Renal Cell Carcinoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Hyper-CVAD in Combination with Venetoclax for the Treatment of Pediatric, Adolescent and Young Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Calaspargase Pegol plus Combination Chemotherapy for the Treatment of Young Adults with Newly Diagnosed Acute Lymphoblastic Leukemia
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Radiosurgery before Surgery for the Treatment of Brain Metastases
Status: Active
Location: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
Status: Active
Location: See ClinicalTrials.gov
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Status: Active
Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma
Status: Active
Location: See ClinicalTrials.gov
Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed And/or Refractory Multiple Myeloma
Status: Active
Location: See ClinicalTrials.gov
A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)
Status: Active
Location: Cancer Therapy and Research Center at The UT Health Science Center at San Antonio, San Antonio, Texas
I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients
Status: Active
Location: See ClinicalTrials.gov
Adding Asciminib to Usual Treatment for Adults With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia
Status: Enrolling by Invitation
Location: 2 locations